Why we should not recommend or offer fluvoxamine to COVID-19 patients?

Eur J Clin Pharmacol. 2023 Feb;79(2):321-322. doi: 10.1007/s00228-022-03447-3. Epub 2022 Dec 23.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19 Drug Treatment
  • COVID-19*
  • Fluvoxamine* / therapeutic use
  • Humans
  • Patients

Substances

  • Fluvoxamine